Elbert Glover

From Wikipedia, the free encyclopedia
Jump to: navigation, search


Elbert D. Glover, PhD is a researcher and writer in the field of tobacco addiction and smoking cessation. He is Professor of Public Health and Chair of the Department of Behavioral and Community Health at the University of Maryland at College Park School of Public Health.

Biography[edit]

He was born in Texas, He graduated from Texas Tech University in 1969, received a masters degree from Texas A&I University in 1972 and a PhD from Texas Woman's University in 1977, all in Health Education. He has taught at Oklahoma State University, Texas Christian University, Texas Woman's University, Texas College of Osteopathic Medicine, Texas A&M University, the University of Kansas, East Carolina University, and West Virginia University.

Research[edit]

His principal interest is the development of cessation aids for people interested in stopping the use of tobacco. He has conducted clinical trials with the use of other delivery forms of nicotine, including gum, transdermal patches, oral nicotine inhalers, nasal spray, and sublingual tablets. He has also studied the use of lobeline as a nicotine blocker,[1] and various psychoactive substances including anti-depressants and anti-anxiety agents. He has also investigated rimonabant (an endocabinnoid, varenicline (a nicotine receptor partial agonist)[2] and 3′AmNic-rEPA (a nicotine conjugate vaccine).[3]

He has received major research grants from the government U.S. Department of Education, Centers for Disease Control, National Cancer Institute, National Institute of Drug Abuse, and National Institutes of Health. He has also received major grants from the manufacturers of the smoking cessations aids or pharmaceuticals ALZ Corporation, AstraZeneca, Bristol-Myers Squibb, Burroughs Wellcome, Ciba-Geigy, DrugAbuse Sciences, DynaGen, Eli Lilly, Glaxo Wellcome, Healthcare Products Development, KABI Pharmacials, Knoll Pharmaceuticals, LEO Pharmaceuticals, Marion Merrell Dow, NABI Pharmaceuticals, Pharmacia, Pfizer, Sano, Sanofi-Synthelabo, SmithKline Beecham, Parke-Davis, Takeda, and Upjohn .[4]

Professional accomplishments[edit]

Glover is publisher and editor of the American Journal of Health Behavior; he is a founder and past president of the American Academy of Health Behavior (AAHB),[5] and in 2003 received their Distinguished Scholar Award. He is a fellow of the American Academy of Health Behavior, the American School Health Association & the Royal Institute of Public Health

Public work[edit]

Glover has appeared on many television programs, including Dateline, 20/20, The Charlie Rose Show, Good Morning America, PM Magazine, Health Talk America, MD-TV, CBS Morning News, Peter Jennings News World Report, and NBC Evening News. His research has been featured in numerous popular publications such as Ladies Home Journal, Newsweek, Readers Digest, Seventeen, Time, and USA Today.[citation needed]

References[edit]

  1. ^ "A Multicenter Phase 3 Trial of Lobeline Sulfate for Smoking Cessation" American Journal of Health Behavior, 34(1), January 2010 , 101-109 [1]
  2. ^ "Varenicline: progress in smoking cessation treatment", Expert Opinion on Pharmacotherapy August 2007, 8(11) 1757-1767 doi:10.1517/14656566.8.11.1757 [2]
  3. ^ "Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic" Clinical Pharmacology & Therapeutics 89, 392-399 (March 2011) doi:10.1038/clpt.2010.317 [3]
  4. ^ [4]
  5. ^ "Formation and Early History of The American Academy of Health Behavior" American Journal of Health Behavior, 34(5), September 2010 , 563-572. [5]
  • Black, R., and Laflin, M. (2003). Viewpoint: Conversation with Elbert D. Glover, PhD, FASHA, FRIPH, FAAHB. American Journal of Health Behavior, 27(6)
  • "Elbert D. Glover . . . Smokeless tobacco researcher," Pieces of Eight, May 1, 1987. [6] ]
  • Nuzzo, R. (2006). "For smokers: A shot at quitting." Los Angeles Times. [7]
  • "Quitters get a shot in the arm" Daily Record (Baltimore, Maryland), July, 2006. [8]

External links[edit]